|Application ||IHC-P, WB, E|
|Calculated MW||23805 Da|
|Other Names||Cyclin-dependent kinase inhibitor 3, CDK2-associated dual-specificity phosphatase, Cyclin-dependent kinase interactor 1, Cyclin-dependent kinase-interacting protein 2, Kinase-associated phosphatase, CDKN3, CDI1, CIP2, KAP|
|Target/Specificity||This CDKN3 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 183-212 amino acids from the C-terminal region of human CDKN3.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein G column, eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||CDKN3 Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Synonyms||CDI1, CIP2, KAP|
|Function||May play a role in cell cycle regulation. Dual specificity phosphatase active toward substrates containing either phosphotyrosine or phosphoserine residues. Dephosphorylates CDK2 at 'Thr-160' in a cyclin-dependent manner.|
|Cellular Location||Cytoplasm, perinuclear region|
Provided below are standard protocols that you may find useful for product applications.
CDKN3 belongs to the dual specificity protein phosphatase family. It was identified as a cyclin-dependent kinase inhibitor, and has been shown to interact with, and dephosphorylate CDK2 kinase, thus prevent the activation of CDK2 kinase. The gene was reported to be deleted, mutated, or overexpressed in several kinds of cancers.
Yeh, C.T., et al., Biochem. Biophys. Res. Commun. 305(2):311-314 (2003).
Yeh, C.T., et al., Cancer Res. 60(17):4697-4700 (2000).
Lee, S.W., et al., Mol. Cell. Biol. 20(5):1723-1732 (2000).
Poon, R.Y., et al., Science 270(5233):90-93 (1995).
Hannon, G.J., et al., Proc. Natl. Acad. Sci. U.S.A. 91(5):1731-1735 (1994).